J Hepatology: α-1抗胰蛋白酶缺乏症在非肝硬化队列中的临床和组织学特征

2018-11-25 MedSci MedSci原创

α-1抗胰蛋白酶缺乏症(AATD)是成人肝脏疾病的罕见原因,因此,本项研究目的是确定未知患有肝硬化的成人AATD人群中肝纤维化的患病率和严重程度,同时确定纤维化的危险因素和检测疾病的生物标志物。

背景与目的
α-1抗胰蛋白酶缺乏症(AATD)是成人肝脏疾病的罕见原因,因此,本项研究目的是确定未知患有肝硬化的成人AATD人群中肝纤维化的患病率和严重程度,同时确定纤维化的危险因素和检测疾病的生物标志物。

方法
研究人员招募了总共94名具有经典基因型'PI * ZZ'AATD的成年人,并进行肝转氨酶和合成功能标志物的检测,瞬时弹性成像和肝脏活组织检查也将用于本项研究。

结果
本项研究结果显示肝纤维化(F≥2)的患病率为35.1%。F≥2组的丙氨酸氨基转移酶,天冬氨酸氨基转移酶和γ-谷氨酰转移酶值较高。α-1抗胰蛋白酶缺乏症与临床纤维化存在显着相关(OR 14.2; 95%CI 3.7-55;p<0.001)。门脉炎症和肝细胞变性与临床上纤维化显着相关。瞬态弹性成像检测F≥2纤维化的准确性是十分优秀的【AUC为0.70(95%CI 0.58-0.82)】。

结论
超过三分之一的患有'PI * ZZ'AATD的无症状和肺部受累成人具有显着的潜在肝纤维化倾向。肝细胞中AAT积聚和基线活检时门静脉炎症的存在下,肝纤维化的风险增加。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1956414, encodeId=5f9a1956414fe, content=<a href='/topic/show?id=967c1911e16' target=_blank style='color:#2F92EE;'>#α-1抗胰蛋白酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19117, encryptionId=967c1911e16, topicName=α-1抗胰蛋白酶)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI5PdY90y5Jib8FnPhCXTR2d9v3K17epNSwB2eb0vmXUldNJl2e72S4unZTAHLAojicdVSialTDFHAxA/132, createdBy=78d82500042, createdName=ms7514935887898259, createdTime=Mon May 20 04:20:00 CST 2019, time=2019-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1926246, encodeId=ce6e19262463c, content=<a href='/topic/show?id=9238e767680' target=_blank style='color:#2F92EE;'>#组织学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77676, encryptionId=9238e767680, topicName=组织学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc0372, createdName=bnurmamat, createdTime=Sun May 12 14:20:00 CST 2019, time=2019-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1945197, encodeId=1fb1194519e15, content=<a href='/topic/show?id=249488e60fe' target=_blank style='color:#2F92EE;'>#蛋白酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88760, encryptionId=249488e60fe, topicName=蛋白酶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Wed Dec 05 04:20:00 CST 2018, time=2018-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427266, encodeId=d227142e26604, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Tue Nov 27 12:20:00 CST 2018, time=2018-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046358, encodeId=8a17104635862, content=谢谢!最新的信息读起来就是收获大, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=guging, createdTime=Mon Nov 26 00:20:00 CST 2018, time=2018-11-26, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1956414, encodeId=5f9a1956414fe, content=<a href='/topic/show?id=967c1911e16' target=_blank style='color:#2F92EE;'>#α-1抗胰蛋白酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19117, encryptionId=967c1911e16, topicName=α-1抗胰蛋白酶)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI5PdY90y5Jib8FnPhCXTR2d9v3K17epNSwB2eb0vmXUldNJl2e72S4unZTAHLAojicdVSialTDFHAxA/132, createdBy=78d82500042, createdName=ms7514935887898259, createdTime=Mon May 20 04:20:00 CST 2019, time=2019-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1926246, encodeId=ce6e19262463c, content=<a href='/topic/show?id=9238e767680' target=_blank style='color:#2F92EE;'>#组织学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77676, encryptionId=9238e767680, topicName=组织学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc0372, createdName=bnurmamat, createdTime=Sun May 12 14:20:00 CST 2019, time=2019-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1945197, encodeId=1fb1194519e15, content=<a href='/topic/show?id=249488e60fe' target=_blank style='color:#2F92EE;'>#蛋白酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88760, encryptionId=249488e60fe, topicName=蛋白酶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Wed Dec 05 04:20:00 CST 2018, time=2018-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427266, encodeId=d227142e26604, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Tue Nov 27 12:20:00 CST 2018, time=2018-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046358, encodeId=8a17104635862, content=谢谢!最新的信息读起来就是收获大, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=guging, createdTime=Mon Nov 26 00:20:00 CST 2018, time=2018-11-26, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1956414, encodeId=5f9a1956414fe, content=<a href='/topic/show?id=967c1911e16' target=_blank style='color:#2F92EE;'>#α-1抗胰蛋白酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19117, encryptionId=967c1911e16, topicName=α-1抗胰蛋白酶)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI5PdY90y5Jib8FnPhCXTR2d9v3K17epNSwB2eb0vmXUldNJl2e72S4unZTAHLAojicdVSialTDFHAxA/132, createdBy=78d82500042, createdName=ms7514935887898259, createdTime=Mon May 20 04:20:00 CST 2019, time=2019-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1926246, encodeId=ce6e19262463c, content=<a href='/topic/show?id=9238e767680' target=_blank style='color:#2F92EE;'>#组织学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77676, encryptionId=9238e767680, topicName=组织学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc0372, createdName=bnurmamat, createdTime=Sun May 12 14:20:00 CST 2019, time=2019-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1945197, encodeId=1fb1194519e15, content=<a href='/topic/show?id=249488e60fe' target=_blank style='color:#2F92EE;'>#蛋白酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88760, encryptionId=249488e60fe, topicName=蛋白酶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Wed Dec 05 04:20:00 CST 2018, time=2018-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427266, encodeId=d227142e26604, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Tue Nov 27 12:20:00 CST 2018, time=2018-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046358, encodeId=8a17104635862, content=谢谢!最新的信息读起来就是收获大, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=guging, createdTime=Mon Nov 26 00:20:00 CST 2018, time=2018-11-26, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1956414, encodeId=5f9a1956414fe, content=<a href='/topic/show?id=967c1911e16' target=_blank style='color:#2F92EE;'>#α-1抗胰蛋白酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19117, encryptionId=967c1911e16, topicName=α-1抗胰蛋白酶)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI5PdY90y5Jib8FnPhCXTR2d9v3K17epNSwB2eb0vmXUldNJl2e72S4unZTAHLAojicdVSialTDFHAxA/132, createdBy=78d82500042, createdName=ms7514935887898259, createdTime=Mon May 20 04:20:00 CST 2019, time=2019-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1926246, encodeId=ce6e19262463c, content=<a href='/topic/show?id=9238e767680' target=_blank style='color:#2F92EE;'>#组织学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77676, encryptionId=9238e767680, topicName=组织学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc0372, createdName=bnurmamat, createdTime=Sun May 12 14:20:00 CST 2019, time=2019-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1945197, encodeId=1fb1194519e15, content=<a href='/topic/show?id=249488e60fe' target=_blank style='color:#2F92EE;'>#蛋白酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88760, encryptionId=249488e60fe, topicName=蛋白酶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Wed Dec 05 04:20:00 CST 2018, time=2018-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427266, encodeId=d227142e26604, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Tue Nov 27 12:20:00 CST 2018, time=2018-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046358, encodeId=8a17104635862, content=谢谢!最新的信息读起来就是收获大, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=guging, createdTime=Mon Nov 26 00:20:00 CST 2018, time=2018-11-26, status=1, ipAttribution=)]
    2018-11-27 gwc384
  5. [GetPortalCommentsPageByObjectIdResponse(id=1956414, encodeId=5f9a1956414fe, content=<a href='/topic/show?id=967c1911e16' target=_blank style='color:#2F92EE;'>#α-1抗胰蛋白酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19117, encryptionId=967c1911e16, topicName=α-1抗胰蛋白酶)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI5PdY90y5Jib8FnPhCXTR2d9v3K17epNSwB2eb0vmXUldNJl2e72S4unZTAHLAojicdVSialTDFHAxA/132, createdBy=78d82500042, createdName=ms7514935887898259, createdTime=Mon May 20 04:20:00 CST 2019, time=2019-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1926246, encodeId=ce6e19262463c, content=<a href='/topic/show?id=9238e767680' target=_blank style='color:#2F92EE;'>#组织学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77676, encryptionId=9238e767680, topicName=组织学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc0372, createdName=bnurmamat, createdTime=Sun May 12 14:20:00 CST 2019, time=2019-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1945197, encodeId=1fb1194519e15, content=<a href='/topic/show?id=249488e60fe' target=_blank style='color:#2F92EE;'>#蛋白酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88760, encryptionId=249488e60fe, topicName=蛋白酶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Wed Dec 05 04:20:00 CST 2018, time=2018-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427266, encodeId=d227142e26604, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Tue Nov 27 12:20:00 CST 2018, time=2018-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046358, encodeId=8a17104635862, content=谢谢!最新的信息读起来就是收获大, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=guging, createdTime=Mon Nov 26 00:20:00 CST 2018, time=2018-11-26, status=1, ipAttribution=)]
    2018-11-26 guging

    谢谢!最新的信息读起来就是收获大

    0

相关资讯

GUT:α1-抗胰蛋白酶Pi * Z变异增加了肝硬化的风险

有研究报道,纯合α1-抗胰蛋白酶(AAT)缺乏会增加肝病患者发展为肝硬化的风险,而杂合子变异的相关性仍不清楚。因此,研究人员评估了对非酒精性脂肪性肝病(NAFLD)或酒精中毒患者的两种最相关的AAT变体('Pi * Z'和'Pi * S')的影响。

J Gastroenterology:骨骼肌质量与脂肪的比值增加可以预测非酒精性脂肪性肝病患者转氨酶的下降

有研究表明骨骼肌质量作为一种营养学指标与多种疾病的预后存在显着关系,因此,研究人员进行了一项回顾性研究来确定骨骼肌和体脂对非酒精性脂肪性肝病(NAFLD)患者肝功能的影响。

J Hepatology: 米多君联合白蛋白在预防等待肝移植的肝硬化患者的并发症中的作用

等待肝移植(LT)的失代偿期肝硬化患者通常会出现可能妨碍他们达到LT标准的并发症。循环功能障碍导致有效的血容量不足和血管收缩系统的激活是肝硬化并发症病理生理学的关键因素。这项研究的目的是探究米多君,一种α-肾上腺素能血管收缩剂与静脉注射白蛋白一起治疗是否能改善循环功能障碍,并预防等待LT的患者出现肝硬化的并发症。

Gastroenterology:Simtuzumab对非酒精性脂肪性肝炎引起的桥接纤维化或代偿性肝硬化治疗无效

有文献报道,赖氨酰氧化酶类似物-2可以通过催化胶原的交联促进肝细胞纤维化的发生。因此研究人员在非酒精性脂肪性肝炎引起的晚期纤维化患者进行了simtuzumab(一种针对赖氨酰氧化酶样2的单克隆抗体)的安全性和有效性的探究,以期检验其在治疗非酒精性脂肪性肝炎引起的晚期纤维化中的作用。

Gastroenterology:FXR激动剂不依赖FGF19而使胆汁酸的合成减少

有文献报道肝细胞和/或肠细胞中的法尼醇X受体(FXR)可以抑制肝胆固醇7α-羟化酶来调节胆汁酸(BA)的合成,而在肠细胞中,该过程需要FGF19的信号传导

J Gastroenterology:Mac-2结合蛋白聚糖异构体(M2BPGi)是评估肝纤维化的新血清生物标志物

众所周知,评估肝纤维化对于预测抗病毒治疗的疗效和患者预后非常重要,而肝脏活检是诊断肝纤维化的金标准,但是其存在侵袭性和诊断准确性方面的问题。虽然评估肝纤维化的非侵入性技术变得越来越重要,但是目前仍然没有可靠的血清替代标记物。因此,本项研究的目的旨在鉴定Mac 2结合蛋白Gylcan异构体(M2BPGi)在是评估肝纤维化中的作用。